PharmaBlock and Ascentage Pharma enter into a strategic partnership
PharmaBlock Sciences, a pioneering service provider throughout the pharmaceutical R&D processes, announced it has entered into a strategic partnership with Ascentage Pharma, a globally-focused, clinical-stage biotechnology company active in the development of novel therapeutics for cancer, chronic hepatitis B (CHB), and age-related diseases. The agreement is aimed at strengthening the cooperation between the two companies in drug development and manufacturing.
As a long-standing Contract Development and Manufacturing Organisation (CDMO) partner of Ascentage Pharma, PharmaBlock has seen many of its development programs advance quickly from discovery to preclinical and clinical manufacturing. Under the terms of the agreement, PharmaBlock becomes the preferred CDMO partner of Ascentage Pharma, and the two companies will continue to further and expand their CDMO partnership for current and future projects. PharmaBlock will comprehensively support Ascentage Pharma to accelerate its novel drug development pipeline with the most sufficient R&D input and manufacturing capacity, along with its innovative technological solutions.
Dr. Ming GUO, Co-founder and CEO of Ascentage Pharma, said:
“PharmaBlock is a reliable and trusted business partner of Ascentage. We appreciate the dedication and professionalism of the PharmaBlock team. I believe that the strategic partnership between the two companies will definitely help us accelerate the new drug development pipeline towards the commercial stage.”
Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to block apoptosis or programmed cell death. The company has built a pipeline of eight clinical drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. The company is conducting more than 40 Phase I/II clinical trials in the US, Australia, and China. HQP1351, the company’s core drug candidate developed for the treatment of drug-resistant chronic myeloid leukemia (CML), has been granted an Orphan Drug Designation (ODD) and a Fast Track Designation (FTD) by the US Food and Drug Administration (FDA), and an NDA for the drug has been submitted in China. To date, Ascentage Pharma has obtained a total of eight ODDs from the FDA for four of the company’s investigational drug candidates.
Dr. Haijun Dong, CEO of PharmaBlock commented:
“With a rich pipeline of assets with first- and best-in-class potentials, Ascentage Pharma is a leading innovative biotechnology company in China with a global footprint. We are so proud to support companies like Ascentage to discover and develop next generation of medicines much needed by the patients”.
Spearheaded by an experienced management and core technical team, PharmaBlock has been providing top-level standard development and manufacturing solutions of RSMs, intermediates, and APIs for both the drug development and commercial stages. Making the most out of its building block capabilities, together with its know-how in chemistry, process development, analytical development, manufacturing and engineering technologies etc., the team has distinguished itself by showing great skill in tackling challenging chemistry, securing reliable supply, controlling costs, and maintaining full compliance of quality and EHS, etc. To further realize safe, efficient and green process development and manufacturing, PharmaBlock has developed an advanced chemistry and engineering technology platform, featuring flow chemistry, micropacked bed hydrogenation, biocatalysis, heterogeneous catalysis, crystallization, solid state chemistry, etc. Their technology platform has enabled more innovative solutions, with shortened lead time and overall cost reduction for development and manufacturing projects.
Ad
More Headlines
